Evidence map›Paper›PMID 33738643›Full record

ArticleEJNMMI research2021

Prognostic superiority of International Prognostic Index over [

F Montes de Jesus, D Dierickx, V Vergote, W Noordzij, R A J O Dierckx, C M Deroose, A W J M Glaudemans, O Gheysens, T C Kwee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Prognostic value of baselineQuantitative imaging in medicine and surgery · 2026
    Article
  2. Article
  3. The role ofQuantitative imaging in medicine and surgery · 2024
    Article
  4. BaselineHemaSphere · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

F Montes de JesusDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands. f.m.montes.de.jesus@umcg.nl.
D DierickxDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.
V VergoteDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.
W NoordzijDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.
R A J O DierckxDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.
C M DerooseDepartment of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.
A W J M GlaudemansDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands.
O GheysensDepartment of Nuclear Medicine, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
T C KweeDepartment of Radiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPost-transplant lymphoproliferative disorders (PTLDs) are a spectrum of hematological malignancies occurring after solid organ and hematopoietic stem cell transplantation. [

resultsA total of 88 patients were included. The 1-, 3-, 5- year overall survival rates were 67%, 58% and 43% respectively. Multivariable analysis indicated that a high IPI (HR: 1.56, 95% CI: 1.13-2.16) and an EBV-negative tumor (HR: 2.71, 95% CI: 1.38-5.32) were associated with poor overall survival. Patients with a kidney transplant had a longer overall survival than any other organ recipients (HR: 0.38 95% CI: 0.16-0.89). IPI was found to be the best predicting parameter of overall survival in our cohort. Whole-body MTV, TLG, time after transplant, hypoalbuminemia and PTLD morphology were not associated with overall survival.

conclusion[

Indexed as

2-[18F]fluoro-2-deoxy-D-glucose positron emission tomographyMetabolic tumor volumePost-transplant lymphoproliferative disorderPrognosisTotal lesion glycolysisVolumetric parameters

Identifiers

PMID33738643
PMCPMC7973341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.